AstraZeneca plc vs Unity Software Inc — how do they compare? AstraZeneca plc trades at $166.95 (market cap $258.17B), while Unity Software Inc trades at $31.8 (market cap $13.39B). The key difference: AstraZeneca plc is far larger — about 19.3× Unity Software Inc's market cap, and AstraZeneca plc pays a 1.87% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals.
| AZN | U | |
|---|---|---|
Market Cap | $258.17B | $13.39B |
Sector | Health | Technology |
52-Week High | $209.48 | $49.47 |
52-Week Low | $137.44 | $17.13 |
Enterprise Value | $284.41B | $13.49B |
Dividend Yield | 1.87% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Unity Software (U) trades at $30.68, down 0.68% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $36.50. Recent earnings show mixed results, with Q3 2025 beating expectations but subsequent quarters missing, while revenue remains stable around $1.8 billion. The company maintains strong gross margins of 62.79% but reports negative net income margins, reflecting ongoing profitability challenges amid strategic shifts toward AI and advertising.
The outlook for Unity hinges on its AI integration and cost management, offering upside if execution improves, but risks include persistent losses, high debt, and competitive pressures. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →